对于三腹吐的透导管疗法:随机试验的元分析
Francesco Tartaglia1, Mauro Gitto1, Alessandro Villaschi1
1Department of Biomedical Sciences; Humanitas University; Pieve Emanuele-, Milan, Italy; IRCCS Humanitas Research Hospital; Rozzano-, Milan, Italy.
International journal of cardiology
|August 13, 2025
概括
过导管三门干预 (TTVI) 与一年后的最佳医疗治疗 (OMT) 相比,对于严重三回 (TR) 患者的硬临床结果没有显著改善. 需要进行更长的后续研究,以充分评估TTVI.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 临床试验 临床试验
背景情况:
- 严重的三腹吐 (TR) 在老年患者中很常见,并且与预后不佳有关.
- 通过导管三门干预 (TTVI) 为高风险的外科候选人提供了不那么侵入性的选择.
- 对于严重的TR,TTVI与最佳医疗疗 (OMT) 的比较有效性尚未得到充分证实.
研究的目的:
- 为了评估与OMT相比,TTVI在患有严重症状TR的患者中的临床结果.
- 综合来自TTVI疗效的随机对照试验 (RCT) 的证据.
主要方法:
- 三项涉及1050名患者的RCT的系统审查和元分析.
- 包括跨导管边缘到边缘修复 (TEER) 和跨导管三门更换 (TTVR).
- 分析了一年的结果:全因死亡率,心血管死亡率,心力衰竭住院治疗 (HFH) 和重新干预.
主要成果:
- 在TTVI和OMT之间,在所有原因死亡率 (OR 1.01),心血管死亡 (OR 1.04) 或HFH (OR 0.87) 中没有发现显著差异.
- TTVI显示出较低的三管再干预率 (OR 0.43) 的趋势,尽管在统计学上并不显著.
- 分析包括了2010年至2024年间发表的三项RCT的数据.
结论:
- 对于严重的TR,TTVI在一年内减少主要临床终点方面没有显著优于OMT.
- 需要进一步研究延长后续期,以澄清TTVI的长期益处.
- 目前的证据表明,OMT仍然是严格的TR管理的可行策略.
相关概念视频
Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
Aortic Regurgitation III: Medical Management
43
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
43
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
52
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
52
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27


